文献速递眼底病与葡萄膜炎

低强度夜间光照治疗年龄相关性黄斑变性:一项随机临床试验

Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2018-01-01

结果显示,12个月内疾病进展在干预组为38.1%(95%CI 18.1%-61.6%),对照组为48.3%(95%CI 29.4%-67.5%),两组差异无统计学意义(Mantel-Haenszel检验,共同比值比=0.763,P=0.495)。干预组视锥细胞暗适应的延迟显著大于对照组(1.66±0.61分钟 vs 0.66±0.49分钟)。未报告与干预相关的不良事件。

要点

  • 夜间低强度光照治疗对早期AMD的12个月疾病进展无显著影响(P=0.495)。
  • 干预组视锥细胞暗适应延迟显著大于对照组(1.66±0.61分钟 vs 0.66±0.49分钟)。
  • 未报告与光照治疗相关的不良事件,患者可接受。

核心结论

  • 夜间低强度光照治疗(峰值505 nm,23 scotopic Td)虽为患者所接受,但12个月内对早期AMD的疾病进展无显著效果。
  • 干预组视锥细胞暗适应延迟显著大于对照组,需进一步研究该不良影响的持久性和原因。

研究设计与样本

  • I/IIa期、前瞻性、概念验证、单中心、非盲法随机对照试验。
  • 按1:1随机分为光照治疗组或不予治疗的对照组。
  • 光照治疗通过发光面罩(峰值505 nm,23 scotopic Td)每晚佩戴,持续12个月。
  • 共同主要结局为疾病进展(发生nAMD或玻璃膜疣体积增加超出重测极限)和视锥细胞暗适应时间常数变化。

主要发现

  • 12个月疾病进展在干预组为38.1%(95%CI 18.1%-61.6%),对照组为48.3%(95%CI 29.4%-67.5%)。
  • Mantel-Haenszel检验共同比值比=0.763,P=0.495。
  • 干预组视锥细胞暗适应延迟为1.66±0.61分钟,对照组为0.66±0.49分钟,干预组显著大于对照组。
  • 未报告与干预相关的不良事件。

临床怎么用

  • 对于早期AMD合并对侧眼nAMD的患者,夜间低强度光照治疗(峰值505 nm,23 scotopic Td)未能显著延缓12个月疾病进展。
  • 该治疗虽为患者所接受且未报告相关不良事件,但需关注其导致的视锥细胞暗适应延迟。

局限性

  • 单中心、非盲法设计。
  • 光照治疗对暗适应不良影响的持久性和原因尚不明确,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the safety, acceptability, and effectiveness of light therapy on the progression of AMD over 12 months. METHODS: This was a phase I/IIa, prospective, proof-of-concept, single-center, unmasked randomized controlled trial. Sixty participants (55 to 88 years) with early AMD in the study eye and neovascular AMD (nAMD) in the fellow eye were recruited from a hospital nAMD clinic. Eligible participants were randomized (ratio 1:1) to receive light therapy or to an untreated control group. Light therapy was delivered via a light-emitting mask (peak 505 nm, 23 scotopic Td), which was worn each night for 12 months. Co-primary outcome measures were disease progression (onset of nAMD or increased drusen volume beyond test-retest limits) and change in time constant of cone dark adaptation. Other main outcomes included adverse events, compliance, and subjective sleep quality data. RESULTS: Disease progression over 12 months was seen in 38.1% (18.1%-61.6% confidence interval [CI]) of intervention participants and 48.3% (29.4%-67.5% CI) of controls (Mantel-Haenszel test, common odds ratio = 0.763, P = 0.495). A significantly larger delay in cone adaptation was observed in the intervention group (1.66 ± 0.61 minutes) than in the control group (0.66 ± 0.49 minutes) over the follow-up period. No reported adverse events were deemed to be associated with the intervention. CONCLUSIONS: Although acceptable to the patients, light therapy did not have a substantial effect on the progression of early AMD over 12 months. Further investigation is necessary to discover the permanency and cause of the adverse effect of light therapy on dark adaptation.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Robinson DG, Margrain TH, Dunn MJ, et al. Low-Level Nighttime Light Therapy for Age-Related Macular Degeneration: A Randomized Clinical Trial. Invest Ophthalmol Vis Sci. 2018. PMID: 30208421. doi:10.1167/iovs.18-24284

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。